Skip to main content

Policies & Disclosures

AbbVie is committed to being fully transparent and compliant with our policies and disclosures.

Our Policies

Funding Disclosure

At AbbVie, we’re passionate about combining advanced science with a deep knowledge of the patient experience and worldwide health care systems to help people live better, more productive lives.

AbbVie is extremely proud to support patient care through the provision of grants to healthcare and patient organisations. In addition, we take pride in helping to subsidise the cost of ongoing learning of NHS healthcare professionals (HCPs) by providing financial support to attend independent third-party medical educational events and conferences. We feel this is aligned to our commitment to support HCPs, and ultimately the health and wellbeing of the patients they serve.

Collaboration of industry with healthcare organisations, patient organisations and HCPs is essential to advance patient care, gain insights into unmet medical needs and progress the development of new medicines.

Transparency is key to ensuring that HCPs and organisations can continue to collaborate to bring new, innovative treatments to patients while ensuring that concerns about the relationship and payments (to reimburse them for their time and expertise) between HCPs/patient organisations and industry are addressed.

In accordance with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, AbbVie’s* disclosure of funding support is published below.

*AbbVie’s acquisition of Allergan completed in 2020. Allergan and AbbVie will maintain separate reporting mechanisms in respect of their 2021 transfers of value to HCOs, HCPs and patient organisations. Allergan transfers of value to patient organisations (2019-2021) can be found here.

Patient organisation funding (2019-2021):

January 2021 - December 2021 (Patient Organisations)

January 2020 - December 2020 (Patient Organisations)

January 2019 - December 2019 (Patient Organisations)

AbbVie, along with other pharmaceutical companies also working with patient organisations in the UK, will also be providing a link to our 2021 patient organisation data to the ABPI for inclusion on Disclosure UK, as part of its ‘Patient organisation data gateway’. This is another important step forward to increase transparency of the information about our collaborations and an opportunity to highlight how we work together for the advancement of high-quality care. 

HCP/ Healthcare organisation funding:

Since 2016, the ABPI has required that its members disclose payments to healthcare organisations and health professionals.

In February 2022, as part of our internal pre-disclosure process, AbbVie wrote to each HCP to review and validate transfers of value ahead of our submission to the ABPI. In alignment with ABPI guidance AbbVie has published its 2021 data here.

If you are an HCP and have an enquiry related to the transparency initiative, please send an email to


UK-ABBV-220447 |  June 2022

Modern Slavery Act Statement

AbbVie Ltd - Modern Slavery Act Transparency Statement

Signed PDF version of the statements from year ending December 2021 can be found here.

UK Tax Strategy Statement


To comply with the UK requirements under paragraph 19(2), schedule 19 of the Finance Act 2016, this tax policy statement has been prepared for AbbVie Ltd and its subsidiary (AbbVie Australasia Holdings Ltd).  The principles outlined in this statement also apply to the other companies in the AbbVie Group which are either incorporated or established in the UK and were registered for UK corporate income tax during 2021 consistent with paragraph 22(2), schedule 19 of the Finance Act 2016.  A list of the relevant entities covered by this strategy is set out in Annex 1.     

Our approach to taxes1

AbbVie is a global biopharmaceutical company formed in 2013 following separation from Abbott Laboratories and materially enhanced following the acquisition of the Allergan Group in 2020. We employ approximately 47,000 people worldwide and deliver medicines to patients in more than 175 countries. Our mission is to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie’s financial performance, including management of tax expense and risk, enables that mission. We are committed to achieving our goals while operating responsibly and delivering meaningful contributions to the communities where we live and work.

Our business activities around the world incur a substantial amount and variety of business taxes. We pay corporate income taxes, customs duties, excise taxes, stamp duties, property taxes, sales and use taxes, value added taxes, employment and other business taxes at the relevant levels in all jurisdictions where applicable. The taxes we pay represent a significant contribution to the communities in which we operate.

Tax governance

Our tax function is led by the Vice President (“VP”) of Tax & Treasury, who reports directly to the Chief Financial Officer(“CFO”). The VP and CFO periodically report to the audit committee of the Board of Directors. AbbVie’s approach to the management of tax risk is grounded in proactively monitoring and complying with the relevant tax laws and regulations in the jurisdictions in which AbbVie operates in order to ensure that the correct amount of taxes are identified and paid at the correct time. Our business tax processes are subject to internal controls, AbbVie’s Global Code of Business Conduct and external audit review.

Tax function

Our tax function supports the business needs of the company. Thus, business transactions and activities circumscribe our approach to taxes. We ensure that the tax positions taken are consistent with the letter and spirit of the relevant tax laws in all affected jurisdictions, and aligned with the economic substance of the business transactions to which they relate.

To address patient needs around the world, AbbVie’s operating business requires a robust global supply chain. That supply chain necessitates structures, contracts and transactions among AbbVie’s affiliated companies. Those intercompany relationships must satisfy local and international tax requirements, which are not always clear or consistent. We manage that complexity by conducting rigorous analyses, often supported by external opinions, to ensure compliance with relevant tax laws. AbbVie does not artificially shift profits to tax haven jurisdictions. AbbVie adheres to the arm’s-length principle in its intercompany dealings, consistent with OECD guidelines and local tax laws.

Level of tax risk we are prepared to accept

While we do not have a prescriptive level of risk, we aim to minimise the risk as far as possible. Tax risks can arise for a number of reasons, including gaps or ambiguities in local tax laws, difficulties in interpreting those laws of the specific context of a transaction, or disagreements among tax authorities as to their respective rights to tax the profits associated with a particular transaction. We mitigate those risks in three principal ways. First, our tax processes, policies and governance function aim to ensure compliance with tax laws in the jurisdictions in which we operate. Second, when we identify a gap or ambiguity in determining the correct application of local tax laws to the specific situation, we seek advice from external advisors to ensure that any tax positions taken are well supported. Finally, we engage with tax authorities to ensure that they have timely access to any information needed to evaluate our tax positions and rationales.

Approach to interacting with tax authorities

We are committed to creating and maintaining open and positive relationships with governments and tax authorities worldwide. We seek to identify and resolve any disagreements in a collaborative and proactive manner, including via participation in continuous compliance / monitoring programmes and advance pricing agreements, where available and appropriate. The programmes provide certainty for both AbbVie and tax authorities over the tax treatment of AbbVie’s business.

For a PDF copy of this tax strategy please click here

Annex 1

This tax strategy applies to the following UK entities:

  • AbbVie Ltd
  • AbbVie Australasia Holdings Limited
  • AbbVie UK Holdco Limited
  • AbbVie Biotherapeutics Limited
  • AbbVie Investments Limited
  • AbbVie Trustee Company Limited
  • Allergan Holdco UK Limited
  • Akarna Therapeutics Limited
  • Pharmax Holding Limited
  • LifeCell EMEA Limited
  • Zeltiq Limited
  • Allergan Holdings Limited
  • Allergan Limited
  • Northwood Medical Innovation Limited
  • Allergan Biologics Limited

Global ethics & compliance policies

A comprehensive listing of all AbbVie policies on transparent and ethical business conduct can be found on our Global website here

Joint and Collaborative Working

Joint Working between Abertawe Bro Morgannwg University Health Board and AbbVie Ltd, is focussed on delivering better healthcare outcomes for Hepatitis C patients in Swansea by improving the efficiency and effectiveness of healthcare services.  An executive summary outlining Joint Working between Abertawe Bro Morgannwg University Health Board and AbbVie Ltd can be found here.

The National Dermatology Nurse Audit is a Collaborative Working Project between the British Dermatology Nursing Group and AbbVie Ltd. It focuses on auditing the current NHS dermatology nursing practice and standard of care against the BDNG’s 2020 Clinical Dermatology Nursing Role Descriptors. An executive summary outlining Collaborative Working between the BDNG and AbbVie Ltd can be found here.

Gender Pay Gap Reporting

Click here for further information about AbbVie’s 2021 Gender Pay Gap data.

Click here for further information about Allergan’s 2021 Gender Pay Gap data.

AbbVie Ltd.'s Board of Directors S.172 Statement

A Signed PDF version of the S172 Financial statement from year ending December 2019 can be found here.

March 2022